Title : Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.

Pub. Date : 2022 Mar

PMID : 34931381






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Combination treatment with pioglitazone and bexarotene increases PPARgamma DNA binding activity and IVL promoter activity (p < 0.01 and p < 0.0001). Bexarotene peroxisome proliferator activated receptor gamma Homo sapiens
2 CONCLUSIONS: Targeting the PPARgamma/RXRalpha heterodimer with pioglitazone and bexarotene was effective in this preclinical project. Bexarotene peroxisome proliferator activated receptor gamma Homo sapiens